We recently reported that internal deletion of PTEN tumor suppressor gene in OPM2 and D47 myeloma lines led to high Akt activation. Re-expression of PTEN induced strong apoptosis and growth inhibition. To understand the biologic importance of the phosphatidylinositol 3 kinase (PI3K)/Akt activation affected by PTEN deletion, we analysed apoptosis and growth inhibition by applying PI3K inhibitors to myeloma lines and by expressing Akt constructs. The PI3K inhibitors preferentially suppressed PTEN-null myeloma growth to those expressing PTEN, indicating that PI3K activation is more critical for growth and survival of those lines with PTEN mutations than others expressing a functional PTEN gene. Since PTEN-null myeloma lines exhibited much stronger Akt activation than PTEN-expressing cells in response to insulin-like growth factor I stimulation, we determined whether Akt could be responsible for PI3K-mediated cell survival and growth of PTEN-null myeloma lines. Expression of an active Akt, but not its kinase dead mutant, reversed wortmannin-and dexamethasone-induced apoptosis and growth inhibition in PTEN-null myeloma lines, suggesting that Akt lies downstream of PI3K for PTEN-null myeloma survival and dexamethasone resistance. In summary, we have provided evidence that PTEN-null myeloma cells are stringently dependent on the PI3K/Akt activation for cell survival. These results may provide a basis to treat myeloma patients with PI3K and Akt inhibitors.
Introduction
Multiple myeloma is a terminal B-cell malignancy. It accounts for about 1% of total cancer cases and 2% of total cancer mortality in the United States. It is the second most common hematopoietic malignancy; yet it remains incurable. About 15 000 Americans die of this disease annually (Niesvizky et al., 1993; Nishimoto et al., 1997; Desikan et al., 1999; Kyle, 2001) . The etiology and the mechanism of disease development are not fully understood (Jelinek, 1999) . It is generally believed that multistep transformation is required for the disease progression (Hallek et al., 1998) . Genetically, chromosome abnormalities including translocations involving immunoglobulin heavy chain locus and deletion of fragments on chromosome 13 have been found in more than 50% of patients (Feinman et al., 1997) .
Activation of growth factor pathways such as interleukin 6 (IL-6) and insulin-like growth factor I (IGF-I) is important for myeloma growth, survival, and drug-resistance (Hallek et al., 1998; Jelinek, 1999) . One critical downstream pathway of these growth factors is the phosphatidylinositol 3 kinase (PI3K)/Akt cascade. PI3K activation generates phosphatidylinositol (PI) phosphates, mainly PI3,4P 2 and PI3,4,5P 3 (PIP 3 ) (Toker and Cantley, 1997) . Increased PIP 3 recruits Akt serine/ threonine kinase to the plasma membrane, where the PI3K-dependent kinase 1 and putative Ser 473 kinase phosphorylates it on Thr 308 and Ser 473, respectively, leading to full Akt activation (Kandel and Hay, 1999; Vanhaesebroeck and Alessi, 2000) . Phosphorylated Akt transmits antiapoptotic signals by phosphorylating its downstream molecules on Ser and Thr residues, such as BAD, caspase 9, and forkhead transcription factors (Scheid and Woodgett, 2001 ). Activation of the PI3K/ Akt pathway has been implicated in many human malignancies (Vivanco and Sawyers, 2002) .
Recently, myeloma cells from patient bone marrow samples were shown to respond to both IGF-I and IL-6 for PI3K activation (Tu et al., 2000) . By using antiphospho-Akt antibody, which detects only the active form of Akt, the same group further demonstrated that Akt activation was dramatically increased in the late stage samples of myeloma patients (Hsu et al., 2001) , thus correlating the PI3K/Akt activation with disease development. Several myeloma cell lines, including OPM2, D47, AF10, MH.60, OCI-My5, RPMI8226, OPM6, and MM.1S, were shown to respond to IGF-I or IL-6 for PI3K and Akt activation Ogawa et al., 2000; Tu et al., 2000; Hideshima et al., 2001; Hsu et al., 2001 Hsu et al., , 2002 . Inhibition of PI3K activity suppressed myeloma growth in several myeloma lines (Ogawa et al., 2000; Tu et al., 2000; Hideshima et al., 2001) . These results clearly suggest that activation of the PI3K/Akt pathway is a common phenomenon in myeloma cell signaling and may affect myeloma survival and tumor development.
In addition to its stimulation by growth factors, the PI3K/Akt pathway is negatively regulated by the tumor suppressor gene PTEN (Cantley and Neel, 1999; Vazquez and Sellers, 2000; Simpson and Parsons, 2001) . PTEN dephosphorylates PIP 3 leading to its decreased level and simultaneous reduction in Akt activity (Maehama and Dixon, 1998) . By employing four myeloma cell lines, we were able to demonstrate the loss of PTEN through internal deletion in OPM2 and D47 myeloma lines, leading to high Akt activation . In a more recent study, we showed that HS-Sultan and UCLA #2 myeloma lines also possessed PTEN point mutations accompanied with high Akt activation (Shi et al., 2002a) . Re-expression of PTEN partially suppressed Akt activity in response to IGF-I stimulation Shi et al., 2002a) and induced apoptosis and growth inhibition (Choi et al., 2002) . Re-expression of PTEN in the OPM2 line suppressed tumorigenecity in an animal model (Ge and Rudikoff, 2000) . These results clearly suggest that loss of PTEN may contribute to myeloma transformation by affecting the PI3K/Akt pathway, critical for cell survival. In contrast to PTEN, another phospholipid phosphatase, called src-homology 2 containing inositol 5-phosphatase, was not able to suppress Akt activity and PTEN-null OPM2 cell growth (Choi et al., 2002) , highlighting the specific negative regulation of the PI3K/ Akt cascade by PTEN in myelomas.
Although PI3K and Akt activation has been clearly demonstrated in myeloma cell signaling, whether Akt is the corresponding downstream molecule for PI3K-mediated PTEN-null myeloma survival has not been investigated. More importantly, whether PTEN-null myelomas are more stringently dependent on the PI3K/Akt activation than PTEN-expressing lines for cell survival has not been demonstrated. This would be a fundamental question to address regarding future patient selection for the treatment with inhibitors targeting the PI3K/Akt pathway. In this study, we have investigated the effects of inhibition and activation of PI3K/Akt pathway on PTEN-null myeloma survival by using PI3K inhibitors and by expressing Akt mutant constructs. Results show that higher sensitivity exists for PTEN-null myeloma than for PTEN-expressing lines to growth inhibition imposed by two PI3K inhibitors.
Strong evidence is also provided that Akt lies downstream of PI3K for PTEN-null myeloma survival and resistance to dexamethasone (Dex) treatment.
Results

Inhibition of PI3K activity preferentially suppresses PTEN-null myeloma growth
Re-expression of PTEN in the PTEN-null myeloma cells reduced Akt activity with the concomitant growth inhibition and apoptosis induction (Choi et al., 2002) . To prove that it is the PI3K/Akt pathway activated by PTEN mutation responsible for PTEN-null myeloma growth, we performed 3-[4,5-dimethlthiazol-2-yl]-2,5-dyphenyl tetrazolium bromide (MTT) colorimetric growth and survival analyses in the presence of wortmannin, a specific inhibitor of PI3K (Arcaro and Wymann, 1993) .
The mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor U0126 (Favata et al., 1998) and Dex were also included to determine their effects on myeloma growth. Activation of Ras/MEK/MAPK pathway through IL-6 stimulation or ras mutations has been known to be important for myeloma cell proliferation (Hallek et al., 1998) . Dex is being clinically used to treat myeloma patients through its ability of inducing apoptosis (Desikan et al., 1999; Kyle, 2001) . As shown in Table 1 summarizing data of three MTT assays, wortmannin in the dose of 100 nm suppressed D47 and OPM2 growth by 69 and 32%, respectively. However, growth of other myeloma lines expressing wild-type PTEN Shi et al., 2002a) was inhibited only weakly by wortmannin, ranging from 14 to 22%. To substantiate the preferential killing of PTEN-null myeloma lines, we applied Ly294002, another inhibitor of PI3K activity (Vlahos et al., 1994) , to the same myeloma lines in an MTT assay. As shown in Figure 1 , while the IC 50 for killing four PTEN-expressing lines was higher than 10 mm (RPMI8226-14.7 mm, OCI-My5 15.0 mm, AF10-16.0 mm, and Brown 15.0 mm), the IC 50 was lower than 5 mm for OPM2 (3.7 mm) and D47 (3.4 mm) PTEN-null lines. These data clearly show the preferential killing of PTEN-null myeloma lines by inhibition of PI3K activity and exclude any possible nonspecific toxicity by either PI3K inhibitor toward PTEN-null myeloma lines. Three MTT experiments were performed in the presence of different inhibitors (Dex, 1 mm; Wort, 100 nm; U0126, 1 mm). Percentage of inhibition was similarly calculated as in Figure 4 . Mean value of inhibition (bolded number) and s.d. are shown for each condition
Contrary to the wortmannin effect, Dex was able to kill most myeloma lines except for Brown (Table 1) . Inhibition of MEK activity by U0126 suppressed myeloma growth by 10-25%, confirming the role of MAPK activation in myeloma growth (Hallek et al., 1998 ) (see also Figure 2 ). Co-addition of wortmannin and Dex or U0126 resulted in an additive or synergistic effect in all myeloma lines, suggesting that wortmanninmediated inhibition was unique and did not overlap with pathways targeted by U0126 and Dex. On the other hand, the additive effect was not very obvious for coaddition of Dex and U0126. Together, these data support the rationale for using PI3K inhibitors to treat myeloma patients either alone or with other drugs and inhibitors, particularly to those patients with PTEN gene mutations in their myeloma cells.
IGF-I and to a lesser extent IL-6 activate Akt pathway dependent on PI3K
To elucidate the molecular mechanism of growth inhibition by wortmannin and U0126, we analysed the status of PI3K/Akt and Ras/MAPK cascades stimulated by IGF-I and IL-6. Dex was also included to test if it could affect these two pathways, as it was able to cooperate with PTEN to induce strong apoptosis (Choi et al., 2002) and with wortmannin to inhibit OPM2 and D47 growth (Table 1) . Synergistic effect of IGF-I and IL-6 on myeloma growth was also described previously (Jelinek et al., 1997) . Whether co-addition of them would affect the MAPK and Akt pathways synergistically was also analysed. As shown in Figure 2 , basal MAPK phosphorylation was observed in both D47 (a) and OPM2 (b) lines even in serum starvation, indicating the constitutive activation of this pathway in myeloma cells. IL-6 stimulation resulted in strong MAPK phosphorylation, which was completely suppressed by U0126, but not by wortmannin, suggesting the specificity of these two inhibitors. On the other hand, IGF-I stimulation did not induce significant MAPK activation, but very strong Akt phosphorylation as reported (Choi et al., 2002; Hyun et al., 2000) . Both weak and strong Akt phosphorylation stimulated by IL-6 and IGF-I, respectively, was largely dependent on PI3K activation, as wortmannin significantly inhibited Akt phosphorylation in both lines. Some weak synergistic activation of Akt was observed in the D47 line in response to IGF-I and IL-6 stimulation ( Figure 2a ) and this was not obvious in the OPM2 line (Figure 2b ). No synergistic effect on MAPK activation was detected when these two growth factors were added simultaneously. Dex did not affect these two pathways stimulated by the two factors alone or together. Our results provide evidence that activation of Akt pathway by both IGF-I and IL-6 depends upon PI3K and IGF-I induces stronger Akt activation than IL-6 in PTEN-null myeloma lines.
Akt lies downstream of PI3K activation and is responsible for PTEN-null cell growth and survival
Our previous results showed the reverse correlation between functional PTEN expression and Akt activation in human myeloma and mouse plasmacytoma lines . To demonstrate potential roles of Akt in PTEN-null myeloma survival and drug resistance directly, we expressed both constitutive active Akt (MyrAkt) and kinase dead Akt (AktK179M/T308A/S473A mutant, abbreviated as MAA) in PTEN-null myeloma cells. Mutation on Lys 179 rendered the molecule incapable of autophosphorylation and mutation on Thr 308 and Ser 473 sites completely blocked Akt activation (Alessi et al., 1996) . Expression of MAA mutant rendered cells to grow very slowly and we obtained its expression only in OPM2 cells, but not in D47 line, indicating the potential inhibitory effect of expressing this mutant at high levels on cell growth.
Three-and 2.5-fold increases in Myr-Akt and Akt-MAA expression, respectively, were detectable by using anti-Akt immunoblot analysis, when compared with endogenous Akt in the PTEN-null lines (Figure 3) . IGF-I stimulation resulted in much slower migration of endogenous Akt in both lines as reported previously Choi et al., 2002) , reinforcing the activation of Akt by IGF-I in myeloma cells lacking PTEN expression. Much slower migration of Myr-Akt was observed even in the nonstimulation conditions, indicating the constitutive activation of Myr-Akt due to the plasma membrane localization by myristoylation. On the other hand, expressed MAA mutant did not show any signs of slow migration, which correlated with loss of phosphorylation on Thr 308 and Ser 473 and autophosphorylation (data not shown).
An MTT assay was subsequently performed to test if manipulation of Akt activity by these two mutants would affect growth inhibition induced by wortmannin and/or Dex. While expression of MAA mutant did not act in a dominant-negative fashion to further OPM2 growth inhibition induced by wortmannin plus Dex (data not shown), expression of the Myr-Akt construct in both OPM2 and D47 lines significantly reversed this inhibition (Figure 4) . The Myr-Akt particularly reversed wortmannin-induced growth inhibition, suggesting that activation of Akt can bypass the inhibitory effect of a PI3K inhibitor.
Apoptosis was subsequently tested using anti-poly (ADP ribose) polymerase (PARP) immunoblotting analyses in both lines expressing the Akt mutants. Cleavage of 116 kDa intact PARP by capspase activation, generating an 85 kDa fragment, represents early apoptosis. As shown in Figure 5 , wortmannin treatment resulted in the 85 kDa PARP fragment production in both parental lines that was increased in the presence of Dex. IGF-I and IL-6 suppressed this synergistic apoptotic induction in both lines, reinforcing their role in myeloma antiapoptosis. Expression of Myr-Akt greatly reduced the 85 kDa PARP production in response to wortmannin and wortmannin plus Dex treatments in the D47/Myr-Akt line. Its expression in the OPM2 line significantly suppressed the cleaved PARP production in response to wortmannin plus Dex. On the other hand, apoptotic induction by wortmannin was weakly increased in OPM2 cells expressing the MAA mutant when compared to that of parental line. Together, our results show that activation of Akt plays a causative role in PTEN-null myeloma survival and growth downstream of PI3K.
Discussion
Recently, we demonstrated that loss of PTEN expression led to high Akt activation in OPM2 and D47 Figure 3 Slower and faster migration of Myr-Akt and Akt-MAA mutant expression, respectively, in myeloma cells on a protein gel analysis. The parental and various Akt infectants were serum starved for 2 h, stimulated with IGF-I and lysed. Equivalent amounts of cell lysates were run on an 8% SDS-PAGE and transferred proteins were immunoblotted with anti-Akt antibody. Faster and slower migrated Akt is marked by a bracket. Fold increases are indicated upon expressing Akt mutants when compared with that of respective parental lines myeloma lines . Re-expression of wild-type PTEN, but not its catalytic inactive C124S mutant, suppressed IGF-I-induced Akt activity, supporting the role of PTEN in negatively regulating the PI3K/Akt pathway by potentially dephosphorylating the PI3K products . PTEN reexpression resulted in increased apoptosis and growth inhibition, suggesting that loss of PTEN expression may contribute to myeloma transformation (Choi et al., 2002) . In the present study, we have further analysed the pathological importance of activating the PI3K/Akt pathway, target of PTEN negative regulation in myeloma transformation. Our results show for the first time that inhibition of the PI3K activity by two inhibitors with different mechanisms preferentially suppressed PTEN-null myeloma growth. Wortmannin had an additive effect with Dex and an MEK inhibitor on suppressing growth of most myeloma lines analysed. While IL-6 mainly induced MAPK activation, IGF-I and, to a lesser extent, IL-6 stimulated Akt activity that is dependent on PI3K. By using two mutants of Akt constructs, we have demonstrated that PI3K-mediated PTEN-null myeloma survival and growth relies on Akt activation.
Although previous investigation has analysed the roles of different drugs and inhibitors in suppressing myeloma growth and inducing apoptosis, we have shown uniquely that PTEN-null myeloma cells were more sensitive to PI3K inhibition than PTEN-expressing lines. Moreover, additive effects of wortmannin with U0126 and Dex on growth inhibition were clearly presented. These results suggest that PTEN-null myeloma cells largely depend upon the PI3K pathway for growth and survival. On the other hand, other PTENexpressing lines possess much lower Akt activity than PTEN-null myeloma cells Shi et al., 2002a) . They may use other alternative pathways or several pathways including PI3K for their survival and malignant transformation. It will thus be very critical for us to determine the rate of PTEN gene mutations directly from myeloma clinical samples and to correlate this mutation with Akt activation, the latter has been shown to occur in the late stage of disease progression (Hsu et al., 2001) . Understanding of PTEN status will help us to select the right patients for more effective therapies by targeting the PI3K/Akt pathway, whose Percentage of growth inhibition is calculated by subtracting the OD reading with the inhibitor(s) from that without inhibitor, dividing the remainder by the reading without inhibitor, and multiplying the number by 100. Wortmannin is abbreviated as wort in the figure and the s.d. is shown as bars in both panels. Statistic calculation was performed with paired ttest by comparing the data of the Myr-Akt expressing line with that of parental line. Po0.01 and Po0.05 are indicated by '*' and 'D', respectively Figure 5 Wortmannin-and Dex-induced apoptosis is suppressed by Myr-Akt expression. Parental and Akt expressing lines were treated with growth factors and inhibitors (wortmannin (300 nm), Dex (1 mm), IL-6 (10 ng/ml), IGF-I (100 ng/ml)) for 12 h in the presence of 5% FBS and lysed. Equivalent amounts of cell lysates were subjected to an immunoblot analysis with anti-PARP. Fold increases in the intensity of the 85 kDa bands compared to nontreated lane in each cell line are shown activation is the key for PTEN-null myeloma survival and drug resistance. For example, if we can demonstrate an antimyeloma effect by PI3K inhibitors in myeloma xenograft animal models, wortmannin or Ly294002 may be used in a very low dose with other antimyeloma drugs directly to treat patients. They may also be applied to treat patient bone marrow or blood samples ex vivo to get rid of the residual myeloma cells before autologous stem cell transplantation. Our recent finding showed that the CCI-779, targeting a PI3K downstream pathway, also preferentially killed PTEN-null myeloma lines (Shi et al., 2002a) . This reinforces the concept of targeting the PI3K pathway to treat myeloma patients with PTEN mutations clinically.
Although our results show high sensitivity of PTENnull myeloma lines to PI3K inhibitors, we do not exclude the involvement of activating the same pathway in other PTEN-expressing lines. As shown in recent publications (Tu et al., 2000; Hsu et al., 2002; Shi et al., 2002b) , both IGF-I and IL-6 were able to activate the PI3K/Akt pathway even in PTEN-expressing lines. IL-6 and IGF-I have been known to be critical paracrine sources for myeloma survival in situ (Gado et al., 2001) . We speculate that the PI3K/Akt activation in the tumor loci will not only confine to those cancer cells with PTEN mutations, but also to those which can get access to high concentration of IL-6 and IGF-I. Wortmannin at a low dose was still able to kill PTEN-expressing myeloma lines, albeit at a low efficiency. Co-addition of wortmannin and Dex resulted in additive growth inhibition of four PTEN-expressing lines (see Table 1 ). Thus, interference with the PI3K and its downstream pathways by small molecule inhibitors together with other antimyeloma drugs may have broad implications for treating myeloma patients, which should not limit to PTEN-null myeloma patients.
To demonstrate the role of Akt in transmitting the PI3K signal in PTEN-null myeloma survival and drugresistance, we expressed both constitutively active and kinase inactive mutants of Akt in two myeloma lines lacking PTEN expression. We experienced difficulty of expressing the MAA mutant in both OPM2 and D47 lines and eventually obtained a low expressing line in the OPM2 cells. In contrast to Myr-Akt, which migrated very slowly on a SDS gel in nonstimulating condition, the MAA mutant was resistant to IGF-I stimulation for slower migration, an indication of no Akt activation (see Figure 3 ). Constitutive Akt activation by Myr-Akt expression and no substrate phosphorylation by Akt-MAA expression were confirmed using Histone H2B as substrate in an Akt kinase activity assay (J Zhang and W Li, unpublished observation). Biologically, reversion of growth inhibition imposed by wortmannin was observed in the Myr-Akt lines, indicating that Akt lies downstream of PI3K for PTEN-null myeloma cell growth. Furthermore, the Myr-Akt cell lines were able to suppress apoptosis induced by wortmannin or wortmannin plus Dex, as determined by anti-PARP Western blot analyses and Annexin V staining (J Zhang and W Li, unpublished observation), fully supporting the role of Akt activation in suppression of apoptosis and Dex resistance of PTEN-null myeloma cells. Our results are consistent with a recent finding where constitutive active Akt suppressed Dex-induced apoptosis in two PTEN-expressing lines (Hsu et al., 2002) . Combined with the biochemical data suggesting Akt activation in many myeloma lines either through PTEN mutations or growth factor stimulation Ogawa et al., 2000; Tu et al., 2000; Hideshima et al., 2001; Hsu et al., 2001 Hsu et al., , 2002 Choi et al., 2002; Shi et al., 2002a, b) , these results demonstrate that Akt is critical for myeloma transformation and may be responsible for Dex resistance clinically.
In summary, we have provided evidence showing that inhibition of PI3K activity preferentially kills PTENnull myeloma cells and cooperates with Dex and U0126 for maximal growth inhibition. Akt lies downstream of PI3K and plays a causative role in PTEN-null myeloma survival and Dex resistance. Thus, future studies in using PI3K/Akt inhibitors either alone or together with other antimyeloma agents will benefit myeloma patients greatly.
Materials and methods
Cell line culture
Culture of OPM2, D47, and Brown cell lines were reported previously Choi et al., 2002) . The AF10 and RPMI8226 lines were maintained in RPMI1640 with 10% fetal bovine serum (FBS), nonessential amino acids, pyruvate, and antibiotics. The OCI-My5 line was kept in Iscove's modified Dulbecco's medium containing the same supplements as for AF10 and RPMI8226.
Reagents
Human IGF-I was purchased from Intergin (Purchase, NY, USA). IL-6 was from R&D Systems (Minneapolis, MN, USA). Wortmannin, Ly294002, and U0126 were ordered from Calbiochem (San Diego, CA, USA). Dex and MTT were purchased from Sigma (St Louis, MO, USA).
Plasmid DNA construction and expression of Akt constructs using retroviral system
The pBabe-Myr-Akt vector was kindly provided by Silvio Gutkind (NIDCR, NIH, Bethesda, MD, USA) (Murga et al., 1998) . To establish an Akt mutant lacking both autophosphorylation, and transphosphorylation on T308 and S473, we first mutated Thr 308 to Ala using the K179 M mutant (Li et al., 1999) GCTGGCCGAGTAGGCGAACTGGGGGAAGTG 3 0 . Successful mutation on Ser 473 to Ala generated an additional BglI site (underlined in the sequences). The final mutant K179M/T308A/S473A (abbreviated as Akt-MAA) cloned in the pBabe retroviral vector was sequenced using an ABI sequencer (not shown). The plasmid DNAs containing both Myr-Akt and Akt-MAA were transfected to the PT67 packaging line (Clontech, Palo Alto, CA, USA) using Lipofectamine (Invitrogen, Carlsbad, CA, USA) and selected with puromycin (1 mg/ml, Calbiochem). Infection and selection of target myeloma cells with the viral supernatants have been reported Li et al., 2000; Choi et al., 2002) .
Western blot analyses
For anti-phospho-Akt, anti-phospho-MAPK, and anti-Akt immunoblot analyses, cells were serum starved for 2 h, stimulated with IGF-I (100 ng/ml) or IL-6 (10 ng/ml) for 10 min. Wortmannin (100 nm), U0126 (1 mm), or Dex (1 mm) was added 20 min before growth factor stimulation. Cell lysation and protein analysis were described previously (Li et al., 1998) . Equivalent amounts of cell lysates were subjected to SDS-PAGE and immunoblotted with anti-P-Akt (Ser 473; New England Biolabs, Beverley, MA, USA), anti-P-MAPK (Thr 202/Tyr 204; New England Biolabs) or anti-Akt (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). For detection of early apoptosis, cells were treated with wortmannin (300 nm), Dex (1 mm), wortmannin plus Dex, IL-6 (10 ng/ ml), IGF-I (100 ng/ml), IL-6 and wortmannin plus Dex, or IGF-I and wortmannin plus Dex for 12 h in the presence of 5% FBS and lysed. Equivalent amounts of cell lysates were separated and blotted with anti-PARP (BD Pharmigen, San Diego, CA, USA). Fold increases in intensity of each band were scanned and analysed using Scan Analysis Program (Biosoft, Ferguson, MO, USA).
MTT assay
The method has been described previously (Choi et al., 2002) . Briefly, 2.5-5 Â 10 4 cells were plated in 200 ml at each well of 96-well plates containing different growth factors and inhibitors, and cultivated in the presence of 2.5-5% FBS for 24-48 h. The MTT dye (125 mg) was added to each well for the last 4 h. Supernatants were decanted and 100 ml DMSO was added. The OD value was read using an ELISA reader at 570 with 650 nm as a reference. The IC 50 (concentration of drug inducing 50% decrease in survival) was determined by extrapolation of results of MTT assays where percentage survival was plotted against log 10 concentration of the drug.
